Literature DB >> 21519148

MMPs in tuberculosis: granuloma creators and tissue destroyers.

Padmini Salgame1.   

Abstract

Most individuals infected with Mycobacterium tuberculosis develop a latent infection, which does not progress to active tuberculosis (TB). This occurs, in part, because infected macrophages recruit immune cells to form a granuloma, isolating the bacteria and preventing its spread. In some individuals, granulomas undergo necrosis and tissue destruction occurs, releasing the bacteria and allowing the development of active disease. In this issue of the JCI, Elkington et al. provide evidence that M. tuberculosis drives the expression of MMP-1, which in turn promotes the collagen breakdown that leads to alveolar destruction in TB. These findings identify putative therapeutic targets for the prevention of TB.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21519148      PMCID: PMC3083780          DOI: 10.1172/JCI57423

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  20 in total

1.  Circulation level of matrix metalloproteinase-9 is correlated with disease severity in tuberculosis patients.

Authors:  E Hrabec; M Strek; M Zieba; S Kwiatkowska; Z Hrabec
Journal:  Int J Tuberc Lung Dis       Date:  2002-08       Impact factor: 2.373

Review 2.  Matrix metalloproteinases as modulators of inflammation and innate immunity.

Authors:  William C Parks; Carole L Wilson; Yolanda S López-Boado
Journal:  Nat Rev Immunol       Date:  2004-08       Impact factor: 53.106

3.  Effect of Mycobacterium tuberculosis and its components on macrophages and the release of matrix metalloproteinases.

Authors:  J C Chang; A Wysocki; K M Tchou-Wong; N Moskowitz; Y Zhang; W N Rom
Journal:  Thorax       Date:  1996-03       Impact factor: 9.139

4.  MMP-1(-1607G) polymorphism as a risk factor for fibrosis after pulmonary tuberculosis in Taiwan.

Authors:  C-H Wang; H-C Lin; S-M Lin; C-D Huang; C-Y Liu; K-H Huang; L-L Hsieh; K F Chung; H-P Kuo
Journal:  Int J Tuberc Lung Dis       Date:  2010-05       Impact factor: 2.373

5.  Treatment with BB-94, a broad spectrum inhibitor of zinc-dependent metalloproteinases, causes deviation of the cytokine profile towards type-2 in experimental pulmonary tuberculosis in Balb/c mice.

Authors:  R Hernandez-Pando; H Orozco; K Arriaga; L Pavön; G Rook
Journal:  Int J Exp Pathol       Date:  2000-06       Impact factor: 1.925

6.  Production of matrix metalloproteinases in response to mycobacterial infection.

Authors:  M Quiding-Järbrink; D A Smith; G J Bancroft
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

Review 7.  Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.

Authors:  Michael A Gardam; Edward C Keystone; Richard Menzies; Steven Manners; Emil Skamene; Richard Long; Donald C Vinh
Journal:  Lancet Infect Dis       Date:  2003-03       Impact factor: 25.071

8.  Unopposed matrix metalloproteinase-9 expression in human tuberculous granuloma and the role of TNF-alpha-dependent monocyte networks.

Authors:  Nicholas M Price; Robert H Gilman; Jasim Uddin; Sixto Recavarren; Jon S Friedland
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

9.  MMP-1 drives immunopathology in human tuberculosis and transgenic mice.

Authors:  Paul Elkington; Takayuki Shiomi; Ronan Breen; Robert K Nuttall; Cesar Augusto Ugarte-Gil; Naomi F Walker; Luísa Saraiva; Bernadette Pedersen; Francesco Mauri; Marc Lipman; Dylan R Edwards; Brian D Robertson; Jeanine D'Armiento; Jon S Friedland
Journal:  J Clin Invest       Date:  2011-04-25       Impact factor: 14.808

Review 10.  Matrix metalloproteinases in lung biology.

Authors:  W C Parks; S D Shapiro
Journal:  Respir Res       Date:  2000-12-29
View more
  26 in total

1.  Tissue factor expression by myeloid cells contributes to protective immune response against Mycobacterium tuberculosis infection.

Authors:  Sambasivan Venkatasubramanian; Deepak Tripathi; Torry Tucker; Padmaja Paidipally; Satyanarayana Cheekatla; Elwyn Welch; Anjana Raghunath; Ann Jeffers; Amy R Tvinnereim; Melissa E Schechter; Bruno B Andrade; Nizel Mackman; Steven Idell; Ramakrishna Vankayalapati
Journal:  Eur J Immunol       Date:  2015-11-10       Impact factor: 5.532

2.  Matrix Metalloproteinase Inhibition in a Murine Model of Cavitary Tuberculosis Paradoxically Worsens Pathology.

Authors:  Alvaro A Ordonez; Supriya Pokkali; Julian Sanchez-Bautista; Mariah H Klunk; Michael E Urbanowski; André Kübler; William R Bishai; Paul T Elkington; Sanjay K Jain
Journal:  J Infect Dis       Date:  2019-01-29       Impact factor: 5.226

3.  Serum and CSF cytokines and matrix metalloproteinases in spinal tuberculosis.

Authors:  Tushar Patil; Ravindra Kumar Garg; Amita Jain; Madhu Mati Goel; Hardeep Singh Malhotra; Rajesh Verma; Gyan Prakash Singh; Praveen Kumar Sharma
Journal:  Inflamm Res       Date:  2014-12-12       Impact factor: 4.575

Review 4.  In-silico modeling of granulomatous diseases.

Authors:  Elliott D Crouser
Journal:  Curr Opin Pulm Med       Date:  2016-09       Impact factor: 3.155

5.  Adjunctive role of MMP-9 inhibition along with conventional anti-tubercular drugs against experimental tuberculous meningitis.

Authors:  Shahnawaz Majeed; Bishan D Radotra; Sadhna Sharma
Journal:  Int J Exp Pathol       Date:  2016-07-06       Impact factor: 1.925

6.  Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases.

Authors:  Naomi F Walker; Simon O Clark; Tolu Oni; Nuria Andreu; Liku Tezera; Shivani Singh; Luísa Saraiva; Bernadette Pedersen; Dominic L Kelly; Julia A Tree; Jeanine M D'Armiento; Graeme Meintjes; Francesco A Mauri; Ann Williams; Robert J Wilkinson; Jon S Friedland; Paul T Elkington
Journal:  Am J Respir Crit Care Med       Date:  2012-02-16       Impact factor: 21.405

7.  Lung Function and Respiratory Symptoms after Tuberculosis in an American Indian Population. The Strong Heart Study.

Authors:  Martha Powers; Tiffany R Sanchez; Thomas K Welty; Shelley A Cole; Elizabeth C Oelsner; Fawn Yeh; Joanne Turner; Marcia O'Leary; Robert H Brown; Max O'Donnell; David Lederer; Ana Navas-Acien
Journal:  Ann Am Thorac Soc       Date:  2020-01

8.  Procollagen III N-terminal propeptide and desmosine are released by matrix destruction in pulmonary tuberculosis.

Authors:  Jo Seddon; Victoria Kasprowicz; Naomi F Walker; Ho Ming Yuen; Henry Sunpath; Liku Tezera; Graeme Meintjes; Robert J Wilkinson; William R Bishai; Jon S Friedland; Paul T Elkington
Journal:  J Infect Dis       Date:  2013-08-06       Impact factor: 5.226

9.  Antimycobacterial drugs modulate immunopathogenic matrix metalloproteinases in a cellular model of pulmonary tuberculosis.

Authors:  Shivani Singh; Andre Kubler; Utpal K Singh; Ajay Singh; Harriet Gardiner; Rajniti Prasad; Paul T Elkington; Jon S Friedland
Journal:  Antimicrob Agents Chemother       Date:  2014-06-02       Impact factor: 5.191

10.  Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment.

Authors:  Mary A De Groote; Payam Nahid; Leah Jarlsberg; John L Johnson; Marc Weiner; Grace Muzanyi; Nebojsa Janjic; David G Sterling; Urs A Ochsner
Journal:  PLoS One       Date:  2013-04-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.